Company Profile for BioAlliance Pharma SA.BioAlliance Pharma is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapeutics and predictive assays in the field of drug resistance, targeting cancer and infectious diseases, including in particular HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . The Company has a balanced portfolio of products and proprietary technologies in various stages of development, from preclinical research to a product approved for marketing. To supply this pipeline of products, BioAlliance maintains a unique network of alliances with leading academic investigators from French research institutions, including Le Centre National de la Recherche Scientifique The Centre national de la recherche scientifique ("National Scientific Research Centre", CNRS) is the largest governmental research organization in France. It involves 26,000 permanent staff (researchers, engineers, and administrative staff) and a further 4,000 temporary (CNRS CNRS Centre National de la Recherche Scientifique (National Center for Scientific Research, France) CNRS Centro Nacional de Referencia Para El Sida (Argentinean National Reference Center for Aids) ), L'Institut National de la Sante et de la Recherche Medicale (INSERM INSERM Institut National de la Santé et de la Recherche Médicale (French Institute of Health and Medical Research) ) and the Institut Pasteur, among others. To exploit the opportunities represented by the BioAlliance pipeline, the company emphasizes four areas of product development: Predictive Assays, with a HIV drug resistance HIV drug resistance Antiretroviral drug resistance AIDS The resistance of a strain of HIV to an agent–eg, a reverse transcriptase inhibitor, which occurs in 5%-20% of those newly infected with HIV test, Phenoscript(TM), currently marketed through distribution partnerships in the US and Europe; Adhesive Technology, with a lead product represented by Miconazole-Lauriad(TM), a once-a-day buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal bio-adhesive tablet developed to provide improved therapy for treatment of candidiasis candidiasis (kăn'dĭdī`əsĭs), infection of the mucous membranes caused by the fungus Candida albicans. Other terms for candidiasis are yeast infection, moniliasis (after a former name of the fungal genus), and thrush, the in cancer and HIV patients receiving chemotherapy or immuno-suppressive drugs. Miconazole-Lauriad(TM) is currently in two Phase III clinical trials in France in head and neck cancer patients following radiotherapy and in HIV patients. The Company plans to file an IND for clinical studies in the US, pending a corporate partnership; Nanotechnology, focused on a portfolio of products including the Transdrug(TM) program with an initial product, Doxorubicin-Transdrug, in a Phase I/II trial being conducted at clinical sites in France for treatment of hepatocellular carcinoma (HCC HCC Hepatocellular Carcinoma (liver cancer) HCC Hertfordshire County Council (administrative region of south eastern England UK) HCC Harford Community College (Maryland) ). Doxorubicin-Transdrug consists of a proprietary polymer used to entrap doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased administered by the intra-arterial route to treat primary liver cancer. HCC is a known resistant cancer without an approved therapy. Additional studies using this delivery nanotechnology are planned for treatment of liver metastasis and refractory solid tumors by the IV route; New Chemical Entities, focused on resistance issues in HIV and cancer that could benefit from intra-cellular targeting, including an anti-HIV integrase inhibitor and cancer drugs covered by 20 exclusive patents and licenses. For additional company background, please visit the BioAlliance Pharma web sites at: www.BioAlliancepharma.com and www.viralliance.com.
Company: BioAlliance Pharma SA
Headquarters Address: 59, boulevard du General Martial Valin
75015 Paris
France
Main Telephone: +33 (0) 1 45 58 76 00
Website: www.bioalliancepharma.com
Type of Organization: Private
Industry: Health: Biotechnology
Key Executives: CEO: Dominique Costantini
COO: Gilles Avenard
Vice President, Business Development:
Richard Keatinge
Public Relations
Contact: Richard Keatinge
Phone: +33 (0) 1 45 58 76 00
Email: richard.keatinge@bioalliancepharma.com
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion